iPSC-derived NK cells with site-specific integration of CAR19 and IL24 at the multi-copy rDNA locus enhanced antitumor activity and proliferation

Abstract

The generation of chimeric antigen receptor-modified natural killer (CAR-NK) cells using induced pluripotent stem cells (iPSCs) has emerged as one of the paradigms for manufacturing off-the-shelf universal immunotherapy. However, there are still some challenges in enhancing the potency, safety, and multiple actions of CAR-NK cells. Here, iPSCs were site-specifically integrated at the ribosomal DNA (rDNA) locus with interleukin 24 (IL24) and CD19-specific chimeric antigen receptor (CAR19), and successfully differentiated into iPSC-derived NK (iNK) cells, followed by expansion using magnetic beads in vitro. Compared with the CAR19-iNK cells, IL24 armored CAR19-iNK (CAR19-IL24-iNK) cells showed higher cytotoxic capacity and amplification ability in vitro and inhibited tumor progression more effectively with better survival in a B-cell acute lymphoblastic leukaemia (B-ALL) (Nalm-6 (Luc1))-bearing mouse model. Interestingly, RNA-sequencing analysis showed that IL24 may enhance iNK cell function through nuclear factor kappa B (NFκB) pathway-related genes while exerting a direct effect on tumor cells. This study proved the feasibility and potential of combining IL24 with CAR-iNK cell therapy, suggesting a novel and promising off-the-shelf immunotherapy strategy.

Keywords

chimeric antigen receptors / immunotherapy / induced pluripotent stem cells / interleukin 24 / natural killer cells

References

1	E Liu, D Marin, P Banerjee, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545-553.
2	JS Miller, Y Soignier, A Panoskaltsis-Mortari, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051-3057.
3	S Mantesso, D Geerts, J Spanholtz, L Ku?erová. Genetic engineering of natural killer cells for enhanced antitumor function. Front Immunol. 2020;11:607131.
4	M Tarannum, R Romee, RM Shapiro. Innovative strategies to improve the clinical application of NK cell-based immunotherapy. Front Immunol. 2022;13:859177.
5	K Ohata, JL Espinoza, X Lu, Y Kondo, S Nakao. Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen. Biol Blood Marrow Transplant. 2011;17(2):205-213.
6	C Brehm, S Huenecke, R Esser, et al. Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy. Cancer Immunol Immunother. 2014;63(8):821-833.
7	KY Teng, AG Mansour, Z Zhu, et al. Off-the-shelf prostate stem cell antigen-directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer. Gastroenterology. 2022;162(4):1319-1333.
8	Z Liu, C Guo, SK Das, et al. Engineering T cells to express tumoricidal MDA-7/IL24 enhances cancer immunotherapy. Cancer Res. 2021;81(9):2429-2441.
9	S Liao, Y Yang, S Chen, et al. IL-24 inhibits endometrial cancer cell proliferation by promoting apoptosis through the mitochondrial intrinsic signaling pathway. Biomed Pharmacother. 2020;124:109831.
10	L Persaud, D De Jesus, O Brannigan, et al. Mechanism of action and applications of interleukin 24 in immunotherapy. Int J Mol Sci. 2016;17(6):869.
11	EL Heipertz, ER Zynda, TE Stav-Noraas, et al. Current perspectives on “off-the-shelf” allogeneic NK and CAR-NK cell therapies. Front Immunol. 2021;12:732135.
12	Y Li, DL Hermanson, BS Moriarity, DS Kaufman. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181-192.e5.
13	L Borges, MA Wallet, CL Bullaughey, et al. Development of multi-engineered iPSC-derived CAR-NK cells for the treatment of B-cell malignancies. Blood. 2021;138(suppl 1):1729-1729.
14	Y Wu, T Gao, X Wang, et al. TALE nickase mediates high efficient targeted transgene integration at the human multi-copy ribosomal DNA locus. Biochem Biophys Res Commun. 2014;446(1):261-266.
15	DM Stults, MW Killen, HH Pierce, AJ Pierce. Genomic architecture and inheritance of human ribosomal RNA gene clusters. Genome Res. 2008;18(1):13-18.
16	Z Wang, H Chen, P Wang, et al. Site-specific integration of TRAIL in iPSC-derived mesenchymal stem cells for targeted cancer therapy. Stem Cells Transl Med. 2022;11(3):297-309.
17	B Liu, F Chen, Y Wu, et al. Enhanced tumor growth inhibition by mesenchymal stem cells derived from iPSCs with targeted integration of interleukin24 into rDNA loci. Oncotarget. 2017;8(25):40791-40803.
18	Z Ni, DA Knorr, CL Clouser, et al. Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms. J Virol. 2011;85(1):43-50.
19	DA Knorr, Z Ni, D Hermanson, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013;2(4):274-283.
20	DL Hermanson, L Bendzick, L Pribyl, et al. Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian cancer. Stem Cells. 2016;34(1):93-101.
21	Y Chen, CA Tristan, L Chen, et al. A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells. Nat Methods. 2021;18(5):528-541.
22	H Kared, S Martelli, TP Ng, SLF Pender, A Larbi. CD57 in human natural killer cells and T-lymphocytes. Cancer Immunol Immunother. 2016;65(4):441-452.
23	X Li, C He, C Liu, et al. Expansion of NK cells from PBMCs using immobilized 4-1BBL and interleukin-21. Int J Oncol. 2015;47(1):335-342.
24	M Ma, R Zhao, X Yang, et al. Low expression of Mda-7/IL-24 and high expression of C-myb in tumour tissues are predictors of poor prognosis for Burkitt lymphoma patients. Hematology. 2018;23(8):448-455.
25	Z Ying, XF Huang, X Xiang, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25(6):947-953.
26	W Leung. Infusions of allogeneic natural killer cells as cancer therapy. Clin Cancer Res. 2014;20(13):3390-3400.
27	ER Levy, JA Clara, RN Reger, DSJ Allan, RW Childs. RNA-seq analysis reveals CCR5 as a key target for CRISPR gene editing to regulate in vivo NK cell trafficking. Cancers (Basel). 2021;13(4):1-18.
28	N Lamers-Kok, D Panella, AM Georgoudaki, et al. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. J Hematol Oncol. 2022;15(1):164.
29	A Merino, J Maakaron, V Bachanova. Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting. Blood Rev. 2023;60:101073.
30	M Naeem, OS Alkhnbashi. Current bioinformatics tools to optimize CRISPR/Cas9 experiments to reduce off-target effects. Int J Mol Sci. 2023;24(7):6261.
31	K Ishida, P Gee, A Hotta. Minimizing off-target mutagenesis risks caused by programmable nucleases. Int J Mol Sci. 2015;16(10):24751-24771.
32	Y Fu, JA Foden, C Khayter, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822-826.
33	Y Luo, Y Wang, J Liu, et al. Generation of TALE nickase-mediated gene-targeted cows expressing human serum albumin in mammary glands. Sci Rep. 2016;6:20657.
34	KV Woan, H Kim, R Bjordahl, et al. Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. Cell Stem Cell. 2021;28(12):2062-2075.e5.
35	F Cichocki, SJC van der Stegen, JS Miller. Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies. Blood. 2023;141(8):846-855.
36	JM Churko, J Lee, M Ameen, et al. Transcriptomic and epigenomic differences in human induced pluripotent stem cells generated from six reprogramming methods. Nat Biomed Eng. 2017;1(10):826-837.
37	X Meng, A Neises, RJ Su, et al. Efficient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone. Mol Ther. 2012;20(2):408-416.
38	B Valamehr, M Robinson, R Abujarour, et al. Platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells. Stem Cell Rep. 2014;2(3):366-381.
39	H Zhu, DS Kaufman. An improved method to produce clinical-scale natural killer cells from human pluripotent stem cells. Methods Mol Biol. 2019;2048: 107-119.
40	M Kanaya, C Philippon, A Cieslar-Pobuda, et al. CAR19 iPSC-derived NK cells utilize the innate functional potential mediated through NKG2A-driven education and override the HLA-E check point to effectively target B cell lymphoma. Blood. 2020;136(suppl 1):34-35.
41	NK Bj?rkstr?m, P Riese, F Heuts, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood. 2010;116(19):3853-3864.
42	S Lopez-Vergès, JM Milush, BS Schwartz, et al. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A. 2011;108(36):14725-14732.
43	CJ Chan, L Martinet, S Gilfillan, et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol. 2014;15(5):431-438.
44	Y Gong, RGJ Klein Wolterink, J Wang, GMJ Bos, WTV Germeraad. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14(1):73.
45	R Dash, SK Bhutia, B Azab, et al. mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev. 2010;21(5):381-391.
46	PB Fisher. Is mda-7/IL-24 a “magic bullet” for cancer? Cancer Res. 2005;65(22):10128-10138.
47	HJ Hu, X Liang, HL Li, et al. Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model. Cancer Immunol Immunother. 2021;70(12):3541-3555.
48	W Lou, Q Chen, L Ma, et al. Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in experimental tumor model. J Mol Med. 2013;91(6):715-725.
49	Y Tang, X Sun, Y Wang, et al. Role of IL-24 in NK cell activation and its clinical implication in systemic lupus erythematosus. Clin Rheumatol. 2021;40(7):2707-2715.
50	D Dabitao, CM Hedrich, F Wang, V Vacharathit, JH Bream. Cell-specific requirements for STAT proteins and type I IFN receptor signaling discretely regulate IL-24 and IL-10 expression in NK cells and macrophages. J Immunol. 2018;200(6):2154-2164.
51	T Miyagi, MP Gil, X Wang, J Louten, WM Chu, CA Biron. High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells. J Exp Med. 2007;204(10):2383-2396.
52	J H?fle, T Trenkner, N Kleist, et al. Engagement of TRAIL triggers degranulation and IFNγ production in human natural killer cells. EMBO Rep. 2022;23(8):e54133.
53	T Lu, R Ma, W Dong, et al. Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19. Nat Commun. 2022;13(1):2576.
54	E Voynova, N Hawk, FA Flomerfelt, et al. Increased activity of a NK-specific CAR-NK framework targeting CD3 and CD5 for T-cell leukemias. Cancers. 2022;14(3):524.
55	Q Hu, Y Zhang, P Wang, et al. IL-24 armored CAR19-T cells show enhanced antitumor activity and persistence. Signal Transduct Target Ther. 2021;6(1):14.
56	Z Hu, Z Li, Y Wu, et al. Targeted B-domain deletion restores F8 function in human endothelial cells and mice. Signal Transduct Target Ther. 2022;7(1):189.